Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials - 15/07/23
Key words : acitretin, adalimumab, apremilast, bimekizumab, cyclosporine, etanercept, feet, guselkumab, hands, imsidolimab, infliximab, ixekizumab, methotrexate, network meta-analysis, Otezla, palmoplantar, palms, psoriasis, pustulosis, secukinumab, soles, spesolimab, tofacitinib, upadacitinib, ustekinumab
Funding sources: Author Jin has received research grant funding from the National Psoriasis Foundation and institutional funding from the University of California, San Francisco. Dr Bhutani has received research grant funding from Novartis and Regeneron. Dr Liao has received research grant funding from AbbVie, Amgen, Janssen, LEO, Novartis, Pfizer, Regeneron, and TRex Bio. No funding sources were relevant to this manuscript. The remaining authors had nothing to disclose. |
|
IRB approval status: Exempt. |
Vol 89 - N° 2
P. 423-425 - août 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?